The dominant #SARSCoV2 variant in the US will soon be KP.3. A KP.2 vaccine induced >3-fold neutralizing titers vs KP.3 compared w/ a JN.1 vaccine (mice) 2 companies asserted they would be ready with a KP.2 vaccine But the FDA is going with a JN.1 vaccine www.fda.gov/media/179144/download pic.twitter.com/BsGLhjIbuQ

📝PERSONAL NOTE—Sometimes I share info that might be unpopular to some. For example, stocking up on certain antiviral flu medications (which FDA does allow for prevention & stopping transmission even if you’re not sick—so much poor info/misinfo from a few ignorant MDs)… But many… pic.twitter.com/RM7iAgz7yq

There is a need for innovative approaches to protect our most vulnerable against diseases like #COVID19 and #flu, as well as a potential opportunity to redefine the burden of respiratory season and advance public health. A combination vaccine that could provide dual protection in… pic.twitter.com/Anjhb5V27l

We announced today that our Phase 3 trial of mRNA-1083, an investigational combination #vaccine against #influenza and #COVID19, has met its primary endpoints. mRNA-1083 comprises components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283,… pic.twitter.com/BRuYBsBVag